AZN vs HCM

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

HCM presents a contradictory profile: it is fundamentally undervalued based on deterministic metrics, with a Piotroski F-Score of 5/9 (Stable) and a current price ($15.24) well below both its Graham Number ($20.72) and Intrinsic Value ($18.55). However, the company's operational health is concerning, characterized by negative revenue growth (-16.5%) and a severe collapse in earnings (-98.1% YoY). While the balance sheet is exceptionally strong with very low debt and high liquidity, the core business is currently unprofitable at the operating level. The investment case relies on a turnaround or a catalyst to realize the analyst target price of $22.85.